(Q33371199)

26 July 2017

Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity study (English)

1 reference

26 July 2017

1 reference

Armando Santoro

9

1 reference

ORCID Public Data File 2021

author name string

Hector Soto Parra

1

1 reference

26 July 2017

Raffaele Cavina

2

1 reference

26 July 2017

Fiorenza Latteri

3

1 reference

26 July 2017

Elisabetta Campagnoli

4

1 reference

26 July 2017

Emanuela Morenghi

5

1 reference

26 July 2017

Walter Torri

6

1 reference

26 July 2017

Giorgio Brambilla

7

1 reference

26 July 2017

Marco Alloisio

8

1 reference

26 July 2017

1 February 2007

1 reference

Investigational New Drugs

26 July 2017

1 reference

26 July 2017

25

1 reference

26 July 2017

1

1 reference

26 July 2017

57-62

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-006-8220-7

26 July 2017

0 references

cites work

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-006-8220-7

Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study

21 January 2018

1 reference

12 December 2020

Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study

1 reference

12 December 2020

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

12 December 2020

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

1 reference

12 December 2020

Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study

1 reference

12 December 2020

Optimal two-stage designs for phase II clinical trials

1 reference

12 December 2020

Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).

1 reference

12 December 2020

Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer.

1 reference

12 December 2020

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days

1 reference

12 December 2020

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project

1 reference

12 December 2020

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

12 December 2020

A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial

1 reference

12 December 2020

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

12 December 2020

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer

1 reference

12 December 2020

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

12 December 2020

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

1 reference

12 December 2020

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

12 December 2020

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

12 December 2020

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Onc

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

10.1007/S10637-006-8220-7

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference